Enterprise Value

113.8M

Cash

241.7M

Avg Qtr Burn

-10.52M

Short % of Float

9.42%

Insider Ownership

2.69%

Institutional Own.

93.19%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer

Approved

Quarterly sales

Approved

Quarterly sales

Retifanlimab (anti-PD-1 mAb) Details
NSCLC (Non-small cell lung carcinoma) or Anal Cancer

NDA

FDA meeting

Vobramitamab duocarmazine (vobra duo) (MGC018) Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Phase 2

Data readout

Enoblituzumab (anti-B7-H3) Details
Head and neck squamous cell carcinoma, Cancer

Phase 2

Update

Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Phase 2

Initiation

Vobramitamab duocarmazine combo w/lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Melanoma, Castration-resistant prostate cancer

Phase 1

Data readout

MGD024 Details
Myelodysplastic syndrome, Acute myeloid leukemia

Phase 1

Data readout

Failed

Discontinued

Flotetuzumab (bispecific CD123 × CD3 DART molecule) Details
Cancer, Multiple myeloma, Acute myeloid leukemia

Failed

Discontinued